1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Market Analysis by Type
  • 1.3.1 Overview: Global Odevixibat Consumption Value by Type: 2021 Versus 2025 Versus 2032
  • 1.3.2 1.2 mg capsules
  • 1.3.3 0.6 mg capsules
  • 1.3.4 200 mcg Granules
  • 1.3.5 600 mcg Granules
• 1.4 Market Analysis by Combination Therapy
  • 1.4.1 Overview: Global Odevixibat Consumption Value by Combination Therapy: 2021 Versus 2025 Versus 2032
  • 1.4.2 Combination of Odevixibat and Bile Acid Sequestrants
  • 1.4.3 Combination of Odevixibat and Hepatoprotective Agents
• 1.5 Market Analysis by Sales Channels
  • 1.5.1 Overview: Global Odevixibat Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
  • 1.5.2 Hospital
  • 1.5.3 Retail
  • 1.5.4 Online
• 1.6 Market Analysis by Production Technology
  • 1.6.1 Overview: Global Odevixibat Consumption Value by Production Technology: 2021 Versus 2025 Versus 2032
  • 1.6.2 Originator
  • 1.6.3 Generic
• 1.7 Market Analysis by Application
  • 1.7.1 Overview: Global Odevixibat Consumption Value by Application: 2021 Versus 2025 Versus 2032
  • 1.7.2 Progressive Familial Intrahepatic Cholestasis (PFIC)
  • 1.7.3 Alagille Syndrome (ALGS)
  • 1.7.4 Cholestatic Pruritus in Children and Adults
  • 1.7.5 Biliary Atresia & Other Rare Cholestatic Liver Diseases 提供一些关于Biliary Atresia的研究论文 奥维昔巴特（Odevixibat）的作用机制是什么？ 奥维昔巴特（Odevixibat）的推荐剂量是多少？
  • 1.7.6 Others
• 1.8 Global Odevixibat Market Size & Forecast
  • 1.8.1 Global Odevixibat Consumption Value (2021 & 2025 & 2032)
  • 1.8.2 Global Odevixibat Sales Quantity (2021-2032)
  • 1.8.3 Global Odevixibat Average Price (2021-2032)

2 Manufacturers Profiles

• 2.1 Ipsen Pharma
  • 2.1.1 Ipsen Pharma Details
  • 2.1.2 Ipsen Pharma Major Business
  • 2.1.3 Ipsen Pharma Odevixibat Product and Services
  • 2.1.4 Ipsen Pharma Odevixibat Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.1.5 Ipsen Pharma Recent Developments/Updates
• 2.2 Albireo Pharma
  • 2.2.1 Albireo Pharma Details
  • 2.2.2 Albireo Pharma Major Business
  • 2.2.3 Albireo Pharma Odevixibat Product and Services
  • 2.2.4 Albireo Pharma Odevixibat Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.2.5 Albireo Pharma Recent Developments/Updates

3 Competitive Environment: Odevixibat by Manufacturer

• 3.1 Global Odevixibat Sales Quantity by Manufacturer (2021-2026)
• 3.2 Global Odevixibat Revenue by Manufacturer (2021-2026)
• 3.3 Global Odevixibat Average Price by Manufacturer (2021-2026)
• 3.4 Market Share Analysis (2025)
  • 3.4.1 Producer Shipments of Odevixibat by Manufacturer Revenue ($MM) and Market Share (%): 2025
  • 3.4.2 Top 3 Odevixibat Manufacturer Market Share in 2025
  • 3.4.3 Top 6 Odevixibat Manufacturer Market Share in 2025
• 3.5 Odevixibat Market: Overall Company Footprint Analysis
  • 3.5.1 Odevixibat Market: Region Footprint
  • 3.5.2 Odevixibat Market: Company Product Type Footprint
  • 3.5.3 Odevixibat Market: Company Product Application Footprint
• 3.6 New Market Entrants and Barriers to Market Entry
• 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

• 4.1 Global Odevixibat Market Size by Region
  • 4.1.1 Global Odevixibat Sales Quantity by Region (2021-2032)
  • 4.1.2 Global Odevixibat Consumption Value by Region (2021-2032)
  • 4.1.3 Global Odevixibat Average Price by Region (2021-2032)
• 4.2 North America Odevixibat Consumption Value (2021-2032)
• 4.3 Europe Odevixibat Consumption Value (2021-2032)
• 4.4 Asia-Pacific Odevixibat Consumption Value (2021-2032)
• 4.5 South America Odevixibat Consumption Value (2021-2032)
• 4.6 Middle East & Africa Odevixibat Consumption Value (2021-2032)

5 Market Segment by Type

• 5.1 Global Odevixibat Sales Quantity by Type (2021-2032)
• 5.2 Global Odevixibat Consumption Value by Type (2021-2032)
• 5.3 Global Odevixibat Average Price by Type (2021-2032)

6 Market Segment by Application

• 6.1 Global Odevixibat Sales Quantity by Application (2021-2032)
• 6.2 Global Odevixibat Consumption Value by Application (2021-2032)
• 6.3 Global Odevixibat Average Price by Application (2021-2032)

7 North America

• 7.1 North America Odevixibat Sales Quantity by Type (2021-2032)
• 7.2 North America Odevixibat Sales Quantity by Application (2021-2032)
• 7.3 North America Odevixibat Market Size by Country
  • 7.3.1 North America Odevixibat Sales Quantity by Country (2021-2032)
  • 7.3.2 North America Odevixibat Consumption Value by Country (2021-2032)
  • 7.3.3 United States Market Size and Forecast (2021-2032)
  • 7.3.4 Canada Market Size and Forecast (2021-2032)
  • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

• 8.1 Europe Odevixibat Sales Quantity by Type (2021-2032)
• 8.2 Europe Odevixibat Sales Quantity by Application (2021-2032)
• 8.3 Europe Odevixibat Market Size by Country
  • 8.3.1 Europe Odevixibat Sales Quantity by Country (2021-2032)
  • 8.3.2 Europe Odevixibat Consumption Value by Country (2021-2032)
  • 8.3.3 Germany Market Size and Forecast (2021-2032)
  • 8.3.4 France Market Size and Forecast (2021-2032)
  • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
  • 8.3.6 Russia Market Size and Forecast (2021-2032)
  • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

• 9.1 Asia-Pacific Odevixibat Sales Quantity by Type (2021-2032)
• 9.2 Asia-Pacific Odevixibat Sales Quantity by Application (2021-2032)
• 9.3 Asia-Pacific Odevixibat Market Size by Region
  • 9.3.1 Asia-Pacific Odevixibat Sales Quantity by Region (2021-2032)
  • 9.3.2 Asia-Pacific Odevixibat Consumption Value by Region (2021-2032)
  • 9.3.3 China Market Size and Forecast (2021-2032)
  • 9.3.4 Japan Market Size and Forecast (2021-2032)
  • 9.3.5 South Korea Market Size and Forecast (2021-2032)
  • 9.3.6 India Market Size and Forecast (2021-2032)
  • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
  • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

• 10.1 South America Odevixibat Sales Quantity by Type (2021-2032)
• 10.2 South America Odevixibat Sales Quantity by Application (2021-2032)
• 10.3 South America Odevixibat Market Size by Country
  • 10.3.1 South America Odevixibat Sales Quantity by Country (2021-2032)
  • 10.3.2 South America Odevixibat Consumption Value by Country (2021-2032)
  • 10.3.3 Brazil Market Size and Forecast (2021-2032)
  • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

• 11.1 Middle East & Africa Odevixibat Sales Quantity by Type (2021-2032)
• 11.2 Middle East & Africa Odevixibat Sales Quantity by Application (2021-2032)
• 11.3 Middle East & Africa Odevixibat Market Size by Country
  • 11.3.1 Middle East & Africa Odevixibat Sales Quantity by Country (2021-2032)
  • 11.3.2 Middle East & Africa Odevixibat Consumption Value by Country (2021-2032)
  • 11.3.3 Turkey Market Size and Forecast (2021-2032)
  • 11.3.4 Egypt Market Size and Forecast (2021-2032)
  • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
  • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

• 12.1 Odevixibat Market Drivers
• 12.2 Odevixibat Market Restraints
• 12.3 Odevixibat Trends Analysis
• 12.4 Porters Five Forces Analysis
  • 12.4.1 Threat of New Entrants
  • 12.4.2 Bargaining Power of Suppliers
  • 12.4.3 Bargaining Power of Buyers
  • 12.4.4 Threat of Substitutes
  • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

• 13.1 Raw Material of Odevixibat and Key Manufacturers
• 13.2 Manufacturing Costs Percentage of Odevixibat
• 13.3 Odevixibat Production Process
• 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

• 14.1 Sales Channel
  • 14.1.1 Direct to End-User
  • 14.1.2 Distributors
• 14.2 Odevixibat Typical Distributors
• 14.3 Odevixibat Typical Customers

15 Research Findings and Conclusion

16 Appendix

• 16.1 Methodology
• 16.2 Research Process and Data Source

According to our (Global Info Research) latest study, the global Odevixibat market size was valued at US$ 185 million in 2025 and is forecast to a readjusted size of US$ 436 million by 2032 with a CAGR of 8.5% during review period.
In 2025, global odevixibat production reached approximately 120,000 units..Odevixibat is an orally administered small-molecule ileal bile acid transport (IBAT) inhibitor used for the treatment of rare cholestatic liver diseases. The drug works by selectively inhibiting the reabsorption of bile acids in the ileum, thereby reducing the accumulation of bile acids in the liver and bloodstream, decreasing intrahepatic cholestasis, alleviating symptoms such as pruritus, and improving liver function parameters. Odevixibat is primarily indicated for diseases such as progressive familial intrahepatic cholestasis (PFIC) and is an important targeted therapy in the field of rare diseases. It has been approved in multiple countries and regions for the treatment of pediatric patients and individuals with rare cholestatic liver disorders.
Odevixibat (brand name Bylvay), as the first oral IBAT inhibitor, is primarily used for the treatment of rare cholestatic liver diseases such as progressive familial intrahepatic cholestasis (PFIC), and is positioned within the rapidly growing rare disease therapeutics market. In recent years, driven by improved diagnosis rates of rare liver diseases, expansion of pediatric indications, and increasing demand for targeted therapies, this class of innovative drugs has demonstrated strong growth potential. Odevixibat has gradually achieved commercial penetration in Europe, the United States, and certain emerging markets, owing to its non-systemic mechanism of action and favorable efficacy in relieving pruritus symptoms. However, due to the extremely small patient population, the overall market size remains limited, and it also faces competition from other IBAT inhibitors and alternative treatments for cholestasis. Therefore, its future market growth will largely depend on indication expansion (such as ALGS), broader market access, and accumulation of long-term clinical data.
This report is a detailed and comprehensive analysis for global Odevixibat market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Odevixibat market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Odevixibat market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Odevixibat market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Odevixibat market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Odevixibat
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Odevixibat market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Ipsen Pharma, Albireo Pharma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Odevixibat market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
1.2 mg capsules
0.6 mg capsules
200 mcg Granules
600 mcg Granules
Market segment by Combination Therapy
Combination of Odevixibat and Bile Acid Sequestrants
Combination of Odevixibat and Hepatoprotective Agents
Market segment by Sales Channels
Hospital
Retail
Online
Market segment by Production Technology
Originator
Generic
Market segment by Application
Progressive Familial Intrahepatic Cholestasis (PFIC)
Alagille Syndrome (ALGS)
Cholestatic Pruritus in Children and Adults
Biliary Atresia & Other Rare Cholestatic Liver Diseases 提供一些关于Biliary Atresia的研究论文 奥维昔巴特（Odevixibat）的作用机制是什么？ 奥维昔巴特（Odevixibat）的推荐剂量是多少？
Others
Major players covered
Ipsen Pharma
Albireo Pharma
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Odevixibat product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Odevixibat, with price, sales quantity, revenue, and global market share of Odevixibat from 2021 to 2026.
Chapter 3, the Odevixibat competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Odevixibat breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Odevixibat market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Odevixibat.
Chapter 14 and 15, to describe Odevixibat sales channel, distributors, customers, research findings and conclusion.